Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.32 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | NCF1 | P14598 | 1/20 | 0.32 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2201139 | 0.84 | HTR2A (0.44) | — | |
| Hydrochloric Acid SCHEMBL5874274 | 0.69 | CYP2D6 (0.46) | CYP19A1ADRB2NCF1PLD1KDM4E | |
| Hydrochloric Acid SCHEMBL5874148 | 0.69 | CYP2D6 (0.46) | CYP19A1ADRB2NCF1PLD1KDM4E | |
| SCHEMBL2203810 | 0.69 | OPRM1 (0.40) | NISCH | |
| SCHEMBL349455 | 0.63 | DRD2 (0.47) | CYP19A1ADRB2NCF1PLD1 | |
| SCHEMBL194227 | 0.62 | — | — | |
| Hydrochloric Acid SCHEMBL5874154 | 0.62 | HTR2A (0.36) | CYP19A1ADRB2NCF1PLD1 | |
| Hydrochloric Acid SCHEMBL5874086 | 0.62 | HTR2A (0.36) | CYP19A1ADRB2NCF1PLD1 | |
| SCHEMBL14943252 | 0.61 | CYP19A1 (0.38) | CYP19A1LMNAGAA | |
| SCHEMBL654291 | 0.60 | HTR2A (0.47) | NISCHGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060281714-A1 | Combinations of a cathepsin k inhibitor and a bisphosphonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss | ZIMMERMANN JOHANN | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281714-A1 | Combinations of a cathepsin k inhibitor and a bisphosphonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss | CTSK, CTSB, CTSZ | CYP19A1 1357/4885NISCH 2288/4885ADRB2 3518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.